Snowball logo
logo
HAE_logo

Haemonetics Corporation

HAE โ€ข NYSE
$119.19+$0.68ย  (0.57%)
Estimate
P/E
57.6
EPS
2.07
Beta
0.608
Growth
Revenue, YoY
5.6%
Net income, YoY
-3%
FCF, YoY
225.61%
Forecast
P/E (FWD)
22.5
EPS (FWD)
5.291
About the company
Ticker
HAE
ISIN
US4050241003
Country
United States of America
Sector (GICS)
Healthcare
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Frequently asked questions

What sector does Haemonetics Corporation (HAE) operate in?

Haemonetics Corporation belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Haemonetics Corporation (HAE) current stock price?

As of the latest data, Haemonetics Corporation stock price is $119.19, with a previous close of $118.51. Haemonetics Corporation gained $0.68 in the last trading session, representing a 0.57% increase.

What is Haemonetics Corporation (HAE) current market capitalization?

Haemonetics Corporation market cap is approximately 5.42 billion.

What is Haemonetics Corporation (HAE) Earnings Per Share (EPS)?

The trailing EPS is $2.07, and the forward EPS is $5.29.

What is Haemonetics Corporation (HAE) Price-to-Earnings (P/E) ratio?

Haemonetics Corporation current P/E ratio is 57.58, with a forward P/E of 22.53.

What is Haemonetics Corporation (HAE) EBITDA?

Haemonetics Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 74.69 million.

Does Haemonetics Corporation (HAE) pay dividends?

No. Haemonetics Corporation does not pay a dividend.

How did Haemonetics Corporation (HAE) perform in its most recent earnings report?

In the last report (June 30, 2026), Haemonetics Corporation posted an EPS surprise of 6.54% and a revenue surprise of 3.5%.

When is Haemonetics Corporation (HAE) next earnings report?

Haemonetics Corporation is expected to release its next earnings report on September 30, 2026.

What is Haemonetics Corporation (HAE) beta (volatility) score?

Haemonetics Corporation has a beta of 0.608, indicating lower volatility than the overall market.